A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis
Description
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.Inclusion and Exclusion Criteria
- Confirmed diagnosis of active uveitis
- 18 years of age or older
- Sign informed consent
- Meet best corrected ETDRS visual acuity
- Uveitis of infectious etiology
- Suspected/confirmed central nervous system or ocular lymphoma
- Primary diagnosis of anterior uveitis
- Uncontrolled glaucoma
- Use of topical oculary medication
- Implanted device
- Significant ocular disease
- Lens/media opacities or obscured ocular media
- Intraocular surgery or treatments
- Capsulotomy
- Ocular or periocular infection
- Pupillary dilation
- History of herpetic infection
- Toxoplasmosis or toxoplasmosis scar
- Ocular malignancy
- Allergy or hypersensitivity to study drug
- Participation in other uveitis trial within 30 days
- Monoclonal antibody treatment or biologic therapy
- Any systemic condition/infection
- Immunosuppressive therapy or immunocompromised
- Malignancy remission
- Females who are pregnant or lactating and females not using adequate contraceptives
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Presentado por
SC CTSI